OncoMatch/Clinical Trials/NCT06904482
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Is NCT06904482 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Haplo-Identical / Cord Blood Transplant for agvhd.
Treatment: Haplo-Identical / Cord Blood Transplant — The purpose of this study is to see if see if adding the specific combination of donors can result in acceptable levels of survival without evidence of disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Allowed: FLT3 mutation
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Allowed: KMT2A (MLL) 11q23 rearrangement
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Allowed: TP53 mutation
poor or intermediate-risk cytogenetics or molecular markers (e.g. Flt 3 mutation, 11q23, del 5, del 7, TP53 mutations, complex cytogenetics)
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG <2
Prior therapy
Cannot have received: autologous stem cell transplant
Exception: allowed if >6 months prior
Prior autologous stem cell transplant or CAR-T within the preceding 6 months
Cannot have received: CAR-T cell therapy
Exception: allowed if >6 months prior
Prior autologous stem cell transplant or CAR-T within the preceding 6 months
Cannot have received: allogeneic transplant
prior allogeneic transplant
Lab requirements
Kidney function
Creatinine clearance < 40ml/min (Cockcroft-Gault)
Liver function
Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) > 3X institutional upper limit of normal; ALT (SGPT) > 3X institutional upper limit of normal
Cardiac function
left ventricular ejection fraction < 40%
Creatinine clearance < 40ml/min (Cockcroft-Gault); Bilirubin > 2X institutional upper limit of normal unless Gilbert syndrome; AST (SGOT) > 3X institutional upper limit of normal; ALT (SGPT) > 3X institutional upper limit of normal; Pulmonary function: DLCOc < 60%; Cardiac: left ventricular ejection fraction < 40%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center · Cleveland, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06904482 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior autologous stem cell transplant, CAR-T cell therapy, allogeneic transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify